Candriam S.C.A. Buys 1,476,646 Shares of Roivant Sciences Ltd. $ROIV

Candriam S.C.A. increased its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 5,399.5% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,503,994 shares of the company’s stock after acquiring an additional 1,476,646 shares during the period. Candriam S.C.A. owned about 0.22% of Roivant Sciences worth $16,951,000 as of its most recent filing with the SEC.

Other large investors have also recently added to or reduced their stakes in the company. CWM LLC lifted its stake in Roivant Sciences by 44.6% in the 2nd quarter. CWM LLC now owns 2,984 shares of the company’s stock valued at $34,000 after purchasing an additional 920 shares during the last quarter. Russell Investments Group Ltd. raised its stake in Roivant Sciences by 94.8% in the first quarter. Russell Investments Group Ltd. now owns 4,588 shares of the company’s stock valued at $46,000 after buying an additional 2,233 shares during the period. UMB Bank n.a. lifted its position in shares of Roivant Sciences by 42.0% in the second quarter. UMB Bank n.a. now owns 5,883 shares of the company’s stock valued at $66,000 after buying an additional 1,740 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of Roivant Sciences by 22.9% in the second quarter. GAMMA Investing LLC now owns 7,978 shares of the company’s stock valued at $90,000 after buying an additional 1,485 shares during the last quarter. Finally, PNC Financial Services Group Inc. boosted its stake in shares of Roivant Sciences by 44.8% during the 1st quarter. PNC Financial Services Group Inc. now owns 10,248 shares of the company’s stock worth $103,000 after acquiring an additional 3,169 shares during the period. Institutional investors and hedge funds own 64.76% of the company’s stock.

Insiders Place Their Bets

In other Roivant Sciences news, CEO Eric Venker sold 200,000 shares of the business’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $20.22, for a total value of $4,044,000.00. Following the completion of the sale, the chief executive officer owned 1,504,959 shares of the company’s stock, valued at $30,430,270.98. The trade was a 11.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In the last ninety days, insiders have sold 5,428,958 shares of company stock valued at $80,491,638. 10.80% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on ROIV shares. Guggenheim increased their price target on Roivant Sciences from $15.00 to $21.00 and gave the company a “buy” rating in a research note on Thursday, September 18th. Bank of America increased their price objective on shares of Roivant Sciences from $12.00 to $16.50 and gave the company a “neutral” rating in a research report on Thursday, September 18th. HC Wainwright raised their target price on shares of Roivant Sciences from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Thursday, September 18th. The Goldman Sachs Group upped their price target on shares of Roivant Sciences from $20.00 to $24.00 and gave the company a “buy” rating in a research note on Thursday, September 18th. Finally, Leerink Partners reissued an “outperform” rating and issued a $29.00 price target on shares of Roivant Sciences in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $22.06.

Roivant Sciences Stock Performance

Shares of Roivant Sciences stock opened at $20.56 on Friday. The firm has a 50-day moving average of $16.85 and a 200-day moving average of $13.27. Roivant Sciences Ltd. has a 52-week low of $8.73 and a 52-week high of $21.35. The stock has a market cap of $14.04 billion, a PE ratio of -36.71 and a beta of 1.23.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.